E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

Pharma-50-transparent_216px_red

Become a Fan

« In re Cuozzo Speed Technologies, LLC (Fed. Cir. 2015) | Main | IPO Webinar on Ex Parte Reexaminations »

February 05, 2015

Comments

Kevin,

All I can say is "what a mess" this ill-considered Goodlatte bill is. Obviously none of the co-sponsors have considered what the unfortunate unintended consequences will be of this bill. Titling this bill "Innovation" is deceitful in the extreme.

EG,

Instead of deceitful (which it may or may not be), and at the risk of being confused with my twin brother Cynical, I tend to look at it in a purely Orwellian doublespeak manner.

Call it what you want, this bill is double-plus ungood.

The comments to this entry are closed.

November 2017

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30